APELLIS PHARMACEUTICAL

Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

01 4 2025 06:00:00 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

28 2 2025 06:05:00 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

24 2 2025 06:00:00 提供 Nasdaq GlobeNewswire

Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN

20 2 2025 01:00:00 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

14 2 2025 06:00:00 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 2 2025 15:05:00 提供 Nasdaq GlobeNewswire

Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)

27 1 2025 15:00:00 提供 Nasdaq GlobeNewswire

Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference

13 1 2025 08:00:00 提供 Nasdaq GlobeNewswire

Apellis Announces Keli Walbert to Join the Board of Directors

10 1 2025 06:00:00 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 1 2025 15:05:00 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

06 1 2025 06:00:00 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 12 2024 15:05:00 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

27 11 2024 06:00:00 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference

12 11 2024 06:00:00 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results

05 11 2024 06:05:00 提供 Nasdaq GlobeNewswire

Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN

26 10 2024 13:00:00 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results

22 10 2024 06:00:00 提供 Nasdaq GlobeNewswire

Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN

16 10 2024 06:00:00 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 10 2024 15:05:00 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day

25 9 2024 06:00:00 提供 Nasdaq GlobeNewswire